Expert Interview
Dissecting the 96-week data from the Phase II FENopta open-label extension (OLE) study of Fenebrutinib in patients with relapsing multiple sclerosis.
Ticker(s): RHHBYInstitution: University of California Irvine
- Associate Professor of Clinical Neurology at UC Irvine.
- Treats 500 patients with MS .
- Clinical interests are in autoimmune diseases, multiple sclerosis, demyelinating neuropathies.
- Currently involved in translational research and clinical trials studying demyelinating autoimmune disease of the central nervous system.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
